Does linear growth improve during infliximab therapy in children with chronically active severe Crohn 's disease?
Height velocity improves and height centile increases during infliximab therapy provided patients are treated prior to or in early puberty. These data support the use of infliximab in young patients with otherwise refractory disease, and suggest that ultimate height in this subset of children with severe CD may be less compromised than with previous therapies.
In advanced melanoma MGMT promoter, methylation correlates with tolerance of therapy, but not with clinical outcome.